Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).

Authors

Institutions

Publication Details

Journal
Journal of the American College of Cardiology
Published
2024-10-28
DOI
https://doi.org/10.1016/j.jacc.2024.09.002
Citations
15
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
6.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Sherif F. Nagueh, Theodore P. Abraham, Roberto Barriales‐Villa, Perry Elliott et al.
15 citations
Journal of the American College of Cardiology
Cardiomyopathy and Myosin Studies
6.03
article

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Sherif F. Nagueh, Theodore P. Abraham, Roberto Barriales‐Villa, Perry Elliott, Artur Oręziak, Stephen B. Heitner, Sara Saberi, Iacopo Olivotto, Jenny Wei, ANJALI TIKU OWENS, Andrew Z. Wang, Albree Tower‐Rader, Mark V. Sherrid, Chiara Melloni, Martin S. Maron, Pablo García‐Pavía, Daniel Jacoby, Ahmad Masri, Fady I. Malik, Stuart Kupfer, Florian Rader, Lisa Meng, Lubna Choudhury, Michael E. Nassif
article en
15 citations

Abstract

In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).

Journal of the American College of CardiologyVol. 84(19)
Northwestern University (US), Cedars-Sinai Medical Center (US), Houston Methodist (US), Oregon Health & Science University (US), University of California, San Francisco (US), University of Michigan (US), British Heart Foundation (GB), Massachusetts General Hospital (US), Hospital Universitario Puerta de Hierro Majadahonda (ES), Lahey Medical Center (US), Meyer Children's Hospital (IT), Centro de Investigación Biomédica en Red (ES), Institute of Cardiology (PL), Saint Luke's Hospital (US), Cytokinetics (United States) (US), Complexo Hospitalario Universitario A Coruña (ES), Duke University Hospital (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Instituto de Investigación Biomédica de A Coruña (ES), University College London (GB), University of Pennsylvania (US)
Cytokinetics
Zero hunger
Openalex Percentile: Top 3%
Cardiomyopathy and Myosin Studies
6.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.